AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid study

This article was originally published here

AbbVie, along with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply